DFEND - Vitamin D in First Episode Psychosis: Neuroprotection Design

South LondonMental Health
Start Date: 1 Dec 2015 End Date: 31 Dec 2018

Could vitamin D supplements help to reduce psychosis?

CLAHRC South London researchers are part of a team investigating the potential benefits of vitamin D supplements on people with at the stages of psychosis. The DFEND (Vitamin D in First Episode Psychosis Neuroprotection Design) study team is made up of health professionals, academic researchers, a pathology company – Viapath, as well as a patient and public involvement group who have helped to lead the research.  

Earlier studies in 2013 and 2016 have found high rates of vitamin D deficiency in people with psychosis but current guidelines about prescribing vitamin D do not take into account the specific needs of people with psychosis.  This study will evaluate new ways of putting research into practice by assessing the effect of vitamin D supplements on mental and physical health in people with psychosis.

The study was adopted in May 2016. It is funded by the Stanley Medical Research Institute and will finish in December 2018.

Both of these studies were adopted by CLAHRC South London because they are closely linked with the CLAHRC’s  theme of improving physical and mental health in people with psychosis.

Contact 
Dr Fiona Gaughran
fiona.p.gaughran@kcl.ac.uk